Biomarker analyses and association with clinical outcomes in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib with or without erlotinib in the phase III SEARCH trial.

Authors

Andrew X. Zhu

Massachusetts General Hospital Cancer Center, Boston, MA

Andrew X. Zhu , Yoon-Koo Kang , Olivier Rosmorduc , T.R. Jeffry Evans , Armando Santoro , Paul J. Ross , Edward Gane , Arndt Vogel , Michael Jeffers , Gerold Meinhardt , Carol Elaine Pena

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2013 Gastrointestinal Cancers Symposium

bookmark_border

The role of tumor vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptors (VEGFR) polymorphisms in the prediction of clinical outcome for advanced hepatocellular carcinoma receiving sorafenib.

First Author: Luca Faloppi

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208.

First Author: Julien Edeline

insert_chart_outlined

Poster

2022 ASCO Gastrointestinal Cancers Symposium

bookmark_border

Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208.

First Author: Julien Edeline

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.

First Author: Josep M Llovet